Intech Investment Management LLC Has $5.57 Million Holdings in DexCom, Inc. $DXCM

Intech Investment Management LLC trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM) by 44.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 82,716 shares of the medical device company’s stock after selling 66,221 shares during the period. Intech Investment Management LLC’s holdings in DexCom were worth $5,566,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Marshall Wace LLP lifted its stake in shares of DexCom by 260.7% during the 2nd quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock worth $333,630,000 after buying an additional 2,762,504 shares during the last quarter. E. Ohman J or Asset Management AB raised its holdings in DexCom by 400.2% in the 3rd quarter. E. Ohman J or Asset Management AB now owns 77,492 shares of the medical device company’s stock valued at $5,214,000 after acquiring an additional 62,000 shares during the period. Zevenbergen Capital Investments LLC lifted its position in DexCom by 10.0% during the third quarter. Zevenbergen Capital Investments LLC now owns 685,433 shares of the medical device company’s stock worth $46,123,000 after acquiring an additional 62,098 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of DexCom by 11.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock worth $14,269,000 after acquiring an additional 21,352 shares during the period. Finally, Freestone Capital Holdings LLC grew its position in shares of DexCom by 32.1% in the second quarter. Freestone Capital Holdings LLC now owns 29,823 shares of the medical device company’s stock valued at $2,603,000 after purchasing an additional 7,242 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Citigroup reissued a “buy” rating and set a $77.00 price target (up from $75.00) on shares of DexCom in a report on Thursday, December 11th. Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. Leerink Partners reissued an “outperform” rating and set a $92.00 target price on shares of DexCom in a report on Tuesday, December 16th. Argus decreased their price target on shares of DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Finally, Barclays reaffirmed an “underweight” rating and set a $72.00 price target (up from $71.00) on shares of DexCom in a research report on Friday, February 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $85.18.

DexCom Stock Performance

Shares of DexCom stock opened at $73.43 on Friday. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. The company has a market cap of $28.26 billion, a PE ratio of 34.97, a price-to-earnings-growth ratio of 1.43 and a beta of 1.49. The company has a 50 day moving average of $70.24 and a 200-day moving average of $69.15. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the previous year, the business earned $0.45 earnings per share. The company’s revenue was up 13.1% on a year-over-year basis. As a group, equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.